Skip to main content
. 2017 Jun 9;15:719–731. doi: 10.1016/j.nicl.2017.06.014

Table 1.

Sample characteristics.

Group SZ BD HC Group comparisons
SZ vs. BD SZ vs. HC BD vs. HC
Demographics, education
Total N 223 190 284
Sex (% female) 95 (42.6) 111 (58.4) 134 (47.2) χ2 = 9.65, p = 1.89E-03 χ2 = 5.32, p = 2.11E-02 χ2 = 0.88, p = 3.48E-01
Age (years) 32.10 ± 9.31 34.99 ± 11.31 35.22 ± 9.60 t = − 2.73, p = 1.96E-02 t = − 3.42, p = 1.99E-03 t = − 0.37, p = 1
Education (years) 12.75 ± 2.49 13.50 ± 2.27 14.15 ± 2.26 t = − 2.36, p = 5.62E-02 t = − 5.43, p < 1E-04 t = − 2.81, p = 1.54E-02
Ethnicity (% caucasian) 180 (80.7) 171 (90) 280 (98.5)



Cognitive domains mean z ± sd (n)
g − 1.64 ± 2.45 (181) − 0.01 ± 2.20 (177) 1.08 ± 1.58 (278) t = − 7.58, p < 1E-04 t = − 14.59, p < 1E-04 t = − 6.19, p < 1E-04
Processing speed − 0.63 ± 0.92 (193) − 0.13 ± 0.92 (177) 0.51 ± 0.82 (283) t = − 5.76, p < 1E-04 t = − 14.90, p < 1E-04 t = − 8.33, p < 1E-04
Verbal learning/memory − 0.45 ± 0.83 (194) 0.06 ± 0.90 (178) 0.25 ± 0.72 (284) t = − 6.07, p < 1E-04 t = − 9.83, p < 1E-04 t = − 2.99, p = 8.56E-03
Executive function − 0.53 ± 0.87 (193) − 0.01 ± 0.69 (178) 0.37 ± 0.49 (284) t = − 7.08, p < 1E-04 t = − 14.41, p < 1E-04 t = − 6.41, p < 1E-04
Working memory/attention − 0.35 ± 0.89 (194) − 0.07 ± 1.01 (177) 0.28 ± 0.99 (284) t = − 3.17, p = 4.79E-03 t = − 7.33, p < 1E-04 t = − 3.72, p = 6.5E-04



Symptomsamean ± sd (n)
Duration of illnessb 10.33 ± 8.15 (220) 13.69 ± 9.91 (188) na t = − 3.7, p = 2.4E-04
PANSS negative 15.55 ± 6.59 (220) 10.11 ± 3.60 (186) na t = 10.5, p < 1E-04
PANSS positive 14.86 ± 5.38 (219) 10.08 ± 3.64 (187) na t = 10.6, p < 1E-04
PANSS total 62.18 ± 17.21 (217) 45.59 ± 10.12 (186) na t = 12, p < 1E-04



Drug use n (%)
Alcohol use last month 131 (58.7) 139 (73.2) 213 (75.0)
Amphetamine last month 8 (3.6) 2 (1.1) 1 (0.4)
Cocaine use last month 4 (1.8) 3 (1.6) 2 (0.7)
Cannabis use last month 17 (7.6) 16 (8.4) 3 (1.1)
AUDIT score mean ± sd (n) 6.51 ± 5.87 (198) 8.05 ± 5.83 (178) 6.10 ± 2.93 (247)



Medication n (%)
Antipsychotic 179 (80.3) 74 (38.9) na
Lithium 2 (0.9) 35 (18.4) na
Antiepileptic 29 (13.0) 82 (43.2) na
Antidepressant 57 (25.6) 52 (27.4) na
Hospitalization (mean ± sd) 2.4 (3.3) 1.6 (2.3) na



Polygenic risk scores (PGRS) (total N = 505)
N 145 144 216
SZ PGRS (mean ± sd) 0.34 ± 0.94 0.11 ± 1.01 − 0.30 ± 0.94 t = 1.72, p = 2.57E-01 t = 6.05, p < 1E-04 t = 4.13, p = 1.26E-04
BD PGRS (mean ± sd) 0.03 ± 0.99 0.22 ± 0.96 − 0.17 ± 1.01 t = − 1.62, p = 3.16E-01 t = 1.84, p = 2E-01 t = 3.61, p = 1E-03

AUDIT: Alcohol Use Disorders Identification Test. SZ = Schizophrenia, BD = Bipolar Disorder, HC = Controls.

a

The median time period between the clinical assessment and MRI scan was 155 days.

b

Defined as years between age at the first occurrence of any psychiatric illness episode (psychotic, affective, or other) and date of MRI scan.